Brad Canino
Stock Analyst at Guggenheim
(3.08)
# 1,202
Out of 5,139 analysts
25
Total ratings
40.91%
Success rate
5.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLTO Galecto | Maintains: Buy | $36 → $40 | $31.48 | +27.06% | 3 | Feb 17, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $30 | $12.54 | +139.23% | 1 | Feb 2, 2026 | |
| CBIO Crescent Biopharma | Initiates: Buy | $35 | $9.71 | +260.64% | 1 | Jan 21, 2026 | |
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.27 | - | 2 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $103.57 | +49.66% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $1.39 | +403.60% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $84.78 | +6.16% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $15.59 | +156.57% | 2 | Oct 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | $90 | $55.65 | +61.73% | 1 | Oct 8, 2025 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $23.41 | -14.57% | 1 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $106.17 | +3.61% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 | $11.03 | +63.19% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $15 | $8.88 | +68.92% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.04 | +292.16% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $13.32 | +440.54% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.58 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $23.33 | +135.75% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $44.31 | -32.30% | 2 | Mar 31, 2021 |
Galecto
Feb 17, 2026
Maintains: Buy
Price Target: $36 → $40
Current: $31.48
Upside: +27.06%
Cullinan Therapeutics
Feb 2, 2026
Initiates: Buy
Price Target: $30
Current: $12.54
Upside: +139.23%
Crescent Biopharma
Jan 21, 2026
Initiates: Buy
Price Target: $35
Current: $9.71
Upside: +260.64%
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.27
Upside: -
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $103.57
Upside: +49.66%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $1.39
Upside: +403.60%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $84.78
Upside: +6.16%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $15.59
Upside: +156.57%
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $55.65
Upside: +61.73%
Olema Pharmaceuticals
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $23.41
Upside: -14.57%
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $106.17
Upside: +3.61%
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $11.03
Upside: +63.19%
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $8.88
Upside: +68.92%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.04
Upside: +292.16%
Sep 4, 2025
Initiates: Buy
Price Target: $72
Current: $13.32
Upside: +440.54%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $8.58
Upside: -
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $23.33
Upside: +135.75%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $44.31
Upside: -32.30%